Lilly Strategy: Timely, Valued Medicines to Patients
Published on:
Dr. Jan Lundberg, EVP science and technology and president Lilly Research Labs, Lilly & Co., sits down to discuss the company?s new approach to drug development and its Phase III pipeline
Dr. Jan Lundberg, EVP science and technology and president Lilly Research Labs, Lilly & Co., sits down to discuss the company’s new approach to drug development and its Phase III pipeline.
For more videos tune in to: